A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in LymphomaNagarajan Pattabiraman(Versar (United States)), Johnvesly Basappa(Fox Chase Cancer Center)CancersOctober 21, 202510.3390/cancers17203389Cited by 0SaveCiteExport RISWatch citationsRelated PapersGlyGen: Computational and Informatics Resources for Glycoscience|Glycobiology|2019|207A Novel Allosteric Inhibitor Targeting IMPDH at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma|Preprints.org|2025|1